Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Regis HealthcareASX:REG -1.46%82 3-Year EBITDA Growth Rate is 26.40% as of Dec. 2025, which is 232% above its 10-year median of 7.95. GuruFocus rates ASX:REG with a GF Score™ of 82/100 and a GF Value™ of A$10.55 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 525 Healthcare Providers & Services companies, Regis Healthcare ranks better than 74.29% on this metric.
During the past 12 months, Regis Healthcare's average EBITDA Per Share Growth Rate was 13.30% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 26.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 13.00% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 6.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of Regis Healthcare was 26.40% per year. The lowest was -2.80% per year. And the median was 7.95% per year.
Regis Healthcare (ASX:REG) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Regis Healthcare 3-Year EBITDA Growth Rate Related Terms
ASX:REG vs HCA, THC, DVA: 3-Year EBITDA Growth Rate Comparison
For the Medical Care Facilities subindustry, Regis Healthcare's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regis Healthcare 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Regis Healthcare's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Regis Healthcare's 3-Year EBITDA Growth Rate falls into.
Regis Healthcare 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 26.40% mean?
Regis Healthcare (ASX:REG) has a 3-Year EBITDA Growth Rate of 26.40% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Regis Healthcare and its competitors. This is 232% above median its historical median of 7.95. According to the industry distribution chart, Regis Healthcare ranks #135 out of 525 companies in the Healthcare Providers & Services industry, placing it in the top 25.7%.
Is Regis Healthcare's 3-Year EBITDA Growth Rate too high?
Regis Healthcare's current 3-Year EBITDA Growth Rate of 26.40% is 232% above median its 10-year median of 7.95. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 10.20. Regis Healthcare's value of 26.40% is 158.8% above this industry median. Based on the distribution chart, Regis Healthcare ranks #135 out of 525 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Regis Healthcare has a GF Score™ of 82/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Regis Healthcare's 3-Year EBITDA Growth Rate compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Regis Healthcare ranks #135 out of 525 companies for 3-Year EBITDA Growth Rate. This puts Regis Healthcare in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 10.20. Regis Healthcare's value of 26.40% is 158.8% above this benchmark. While the company's 10-year median is 7.95 vs. the industry median of 10.20, Regis Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.20, based on 525 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Regis Healthcare's current 3-Year EBITDA Growth Rate of 26.40% is 158.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Regis Healthcare and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regis Healthcare's current 3-Year EBITDA Growth Rate is 26.40%, which is 232% above median its own 10-year median of 7.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regis Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Regis Healthcare (ASX:REG) is currently considered Possible Value Trap. The stock's GF Value™ is A$10.55, compared to a current price of A$6.08 — trading 42.4% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 26.40%, which is 232% above median its 10-year median of 7.95 and 158.8% above the Healthcare Providers & Services industry median of 10.20. Regis Healthcare's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Regis Healthcare (ASX:REG), the current 3-Year EBITDA Growth Rate is 26.40% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Regis Healthcare (ASX:REG) Overvalued in 2026?
Based on GuruFocus' analysis, Regis Healthcare stock appears to be undervalued.
The current stock price of A$6.08 is trading 42.4% below its estimated GF Value™ of A$10.55.
GuruFocus considers Regis Healthcare to be Possible Value Trap.
Key valuation signals for ASX:REG:
3-Year EBITDA Growth Rate: 26.40% (232% above median its 10-year median of 7.95)
GF Value™: A$10.55 vs. price of A$6.08 (42.4% below fair value)
Industry Position: 158.8% above the Healthcare Providers & Services median (#135 of 525)
No single metric tells the full story. See the ASX:REG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Regis Healthcare is an Australian residential aged care operator providing accommodation and care for individuals who require high levels of support due to health or mobility issues. Residents are typically over 85 years old and are typified by dementia, palliative care, incontinence, and falls risk. Regis also operates smaller retirement village and home care businesses.
82GF Score
Get the complete analysis for ASX:REG
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:REG has been successfully added to your 
